Strata Critical Medical, Inc. (SRTA) Stock Analysis
After selling its passenger business, SRTA becomes a “toll booth” on U.S. organ transplantation—pairing asset-light logistics with expanding clinical recovery/NRP services to drive an infrastructure-style re-rating.
Overview
Strata Critical Medical (SRTA), formerly Blade Air Mobility, completed a major strategic transformation by divesting its consumer passenger division to Joby Aviation on Aug 29, 2025 (~$125M transaction value) and refocusing exclusively on the U.S. organ transplant logistics and clinical services market. The shift replaces cyclical, capital-intensive urban air mobility exposure with non-discretionary, time-critical healthcare demand. SRTA now operates an integrated “One Call” model serving Organ Procurement Organizations (OPOs) and transplant hospitals, coordinating air/ground transport and, increasingly, clinical recovery and perfusion services. Revenue is split between a Logistics segment (end-to-end transport using an asset-light network complemented by ~30 owned/leased aircraft) and a Clinical segment boosted by the Keystone Perfusion acquisition (surgical recovery, NRP, and perfusion staffing). Structural tailwinds—persistent organ shortages and CMS Tier-based performance pressure on OPOs—favor scaled, reliable providers. Entering FY2026, SRTA guides to rapid growth, expanding EBITDA, and improving free cash flow, positioning the stock as a potential healthcare-infrastructure re-rating candidate if execution continues.